Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GEN2 in Refractory Patients With Primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver

Next Previous
Search
Trial Profile

A Phase 1 Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of GEN2 in Refractory Patients With Primary Hepatocellular Carcinoma or Tumors Metastatic to the Liver

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEN 2 (Primary) ; GEN 2 (Primary) ; GEN 2 (Primary) ; Valganciclovir
  • Indications Liver cancer; Liver metastases; Solid tumours
  • Focus Adverse reactions
  • Acronyms GEN2
  • Sponsors GenVivo

    • Most Recent Events

    • 08 Nov 2024 According to a GenVivo media release, the company will present a poster highlighting the data from the study at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-10, in Houston, TX.
    • 06 Nov 2024 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2024 According to a GenVivo media release, the company look forward to advancing to the expansion phase once the appropriate dose is identified.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top